Captisol technology
WebOct 23, 2024 · The Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. The Pfenex Expression ... WebThe Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. The Pfenex …
Captisol technology
Did you know?
WebCaptisol. Ligand’s Captisol ® technology is a patent protected, uniquely modified cyclodextrin, with a chemical structure that was rationally designed to enable the creation … WebOct 23, 2024 · The Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. The …
WebSummary. Captisol ® is a patent-protected, uniquely modified cyclodextrin, whose chemical structure was rationally designed to enable the creation of new products by significantly … WebFeb 3, 2024 · The Captisol ® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.
WebKansas Higuchi Biosciences Center .The technology of Captisol is used to address the limitations of drugs currently on the market. Captisol-enabled, FDA-approved drugs are sold by Pfizer, Bristol-Myers Squibb, and Baxter International. ... Captisol is an excipient used to improve solubility in certain medication injectable products, Captisol is ... WebMay 27, 2024 · Remdesivir’s formulation includes the solubilizer Captisol, developed at KU, which allows remdesivir be administered to the patient. Captisol was invented and patented by Valentino Stella, University Distinguished Professor Emeritus, and Roger Rajewski, research professor in the Department of Pharmaceutical Chemistry.
WebCaptisol® is a patent protected, uniquely modified cyclodextrin, whose chemical structure was rationally designed to enable the creation of new products by significantly improving solubility, stability, bioavailability and dosing of active pharmaceutical ingredients (APIs). ... Captisol, a Ligand technology. 3911 Sorrento Valley Road. Suite ...
WebJan 14, 2011 · In the event that a product involving the Company Technology is sold as a single product, component, or service, or in the event that the sale is of a pharmaceutical product that is enhanced or enabled by integration with the Captisol technology, then Revenue shall include 100% of the revenues or other assets received from such sale or … trailer hub and bearingsWebDec 20, 2002 · CAPTISOL® SUPPLY AGREEMENT BY AND BETWEEN CYDEX, INC. AND THE HOVIONE GROUP Dated as of December 20, 2002 CAPTISOL® SUPPLY AGREEMENT from Ligand Pharmaceuticals Incorporated filed with the Securities and Exchange Commission. ... Given the financial subsidies and technology transfer … the schweppe mansion historyWebNov 26, 2024 · Veklury is developed using the Captisol technology and Gilead gained a regulatory nod for the drug to treat severe COVID-19 patients. Gilead recorded Veklury’s … trailer hub and spindle assemblyWebJun 1, 2024 · "In 2001, I was fortunate to join a team of scientists and business entrepreneurs, many of whom are KU graduates, to develop and commercialize the nascent Captisol technology," said James Pipkin ... trailer hub and bearingWebMar 23, 2024 · The Captisol ® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand’s Pelican Expression Technology ® is a robust, validated, cost-effective and scalable platform for recombinant protein production that is especially well-suited for ... trailer house wood panelingWebNov 26, 2024 · Ligand’s Captisol technology should continue to be a key revenue driver with rising demand for its partnered drugs and potential approval to the new Captisol-based drugs. New deals will also... the schwinger modelWebAny transfer of CyDex’s Captisol manufacturing technology (which shall not include technology which is proprietary to the Third Party Manufacturer or Pfizer) to MDCO or its contract manufacturer shall be subject to contractual covenants reasonably satisfactory to CyDex regarding confidentiality, limitations on use and non-competition. ... the schwerin family